Related Experiment Video

Updated: Jul 12, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

New horizons in lung cancer management through ATR/CHK1 pathway modulation

Riya Thapa1, Obaid Afzal2, Asif Ahmad Bhat1

  • 1School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India.

Future Medicinal Chemistry
|October 25, 2023
PubMed

Insights

Targeting the ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway shows promise for lung cancer treatment. Inhibitors of ATR/CHK1 are being investigated to overcome drug resistance and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer remains a leading cause of cancer mortality globally.
  • Molecular profiling has refined lung cancer classification, advancing research and therapeutic strategies.
  • The ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway is vital for genomic stability and implicated in lung cancer development and resistance.

Purpose of the Study:

  • To explore the role of the ATR/CHK1 pathway in lung cancer.
  • To review the potential of targeting the ATR/CHK1 pathway for lung cancer treatment.

Main Methods:

  • Review of clinical and preclinical studies on the ATR/CHK1 pathway.
  • Exploration of the function of ATR and CHK1 proteins in DNA damage repair.

Main Results:

  • Activation of the ATR/CHK1 pathway is associated with lung cancer, drug resistance, and poor prognosis.
  • Targeting the ATR/CHK1 pathway has shown promising results in preclinical and clinical investigations.

Conclusions:

  • The ATR/CHK1 pathway is a significant target for novel lung cancer therapies.
  • ATR/CHK1 inhibitors are under active investigation for their therapeutic potential in lung cancer treatment.
Keywords:
ATRCHK1DNA damageNSCLCSCLCcancerlung cancer

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K